SEC Comment Letter for NORTHWEST BIOTHERAPEUTICS INC (NWBO) (CIK 0001072379) (NWBO) — Jan 10, 2012
NORTHWEST BIOTHERAPEUTICS INC (NWBO) (CIK 0001072379)
Date: Jan. 10, 2012 · CIK: 0001072379 · Accession: 0000000000-12-001520
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-33393
Letter
January 10, 2012 Via E-Mail Linda M. Powers Presidents and Chief Executive Officer Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, Maryland 20814 Re: Northwest Biotherapeutics, Inc. Preliminary Information Statement on Schedule 14C Filed December 16, 2011 File No. 000-33393
Dear Ms. Powers: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi lings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely,
/s/ Jeffrey Riedler Jeffrey Riedler Assistant Director
Show Raw Text
January 10, 2012 Via E-Mail Linda M. Powers Presidents and Chief Executive Officer Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, Maryland 20814 Re: Northwest Biotherapeutics, Inc. Preliminary Information Statement on Schedule 14C Filed December 16, 2011 File No. 000-33393 Dear Ms. Powers: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi lings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Jeffrey Riedler Jeffrey Riedler Assistant Director